TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
+24.49%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.63B
AUM Growth
+$415M
(+19%)
Cap. Flow
+$6.14M
Cap. Flow
% of AUM
0.23%
Top 10 Holdings %
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6
Top Buys
| 1 |
AbbVie
ABBV
|
$18.9M |
| 2 |
UnitedHealth
UNH
|
$15.7M |
| 3 |
Moderna
MRNA
|
$15.3M |
| 4 |
CVS Health
CVS
|
$14.4M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$10.6M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$28M |
| 2 |
Biogen
BIIB
|
$26.5M |
| 3 |
Gilead Sciences
GILD
|
$23.6M |
| 4 |
Illumina
ILMN
|
$18.8M |
| 5 |
Cigna
CI
|
$11.8M |
Sector Composition
| 1 | Healthcare | 95.26% |
| 2 | Real Estate | 2.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $22.8M | 0.87% |
410,153
+10,896
| +3% | +$606K |
|
27
Boston Scientific
BSX
$159B
| $22.6M | 0.86% |
644,935
+57,273
| +10% | +$2.01M |
|
28
Sarepta Therapeutics
SRPT
$1.93B
| $22.5M | 0.86% |
140,129
| – | – |
|
29
Exelixis
EXEL
$10.1B
| $22.2M | 0.84% |
933,949
+418,824
| +81% | +$9.94M |
|
30
Intuitive Surgical
ISRG
$163B
| $19M | 0.72% |
100,017
-2,100
| -2% | -$399K |
|
31
Humana
HUM
$37.5B
| $18.8M | 0.72% |
48,506
+2,376
| +5% | +$921K |
|
32
Alnylam Pharmaceuticals
ALNY
$59.4B
| $18.6M | 0.71% |
125,867
-11,750
| -9% | -$1.74M |
|
33
Becton Dickinson
BDX
$54.8B
| $18.6M | 0.71% |
79,698
| – | – |
|
34
Centene
CNC
$14.1B
| $18.3M | 0.7% |
288,194
| – | – |
|
|
IMMU
35
DELISTED
Immunomedics Inc
IMMU
| $17.6M | 0.67% |
497,103
+10,000
| +2% | +$354K |
|
36
Sanofi
SNY
$111B
| $16.7M | 0.64% |
327,367
| – | – |
|
37
McKesson
MCK
$86B
| $16.5M | 0.63% |
107,537
+48,012
| +81% | +$7.37M |
|
38
Viatris
VTRS
$12B
| $16.3M | 0.62% |
1,010,754
| – | – |
|
|
39
Cigna
CI
$81.2B
| $15M | 0.57% |
79,988
-62,667
| -44% | -$11.8M |
|
40
Novartis
NVS
$249B
| $14.9M | 0.57% |
171,008
-8,839
| -5% | -$772K |
|
|
ONC
41
BeOne Medicines Ltd. American Depositary Shares
ONC
$35.1B
| $14.1M | 0.54% |
74,984
| – | – |
|
42
Edwards Lifesciences
EW
$47.5B
| $14M | 0.53% |
202,146
| – | – |
|
|
PRAH
43
DELISTED
PRA Health Sciences, Inc.
PRAH
| $14M | 0.53% |
143,508
| – | – |
|
44
Bio-Techne
TECH
$8.23B
| $13.7M | 0.52% |
206,840
-23,924
| -10% | -$1.58M |
|
45
AstraZeneca
AZN
$254B
| $12.4M | 0.47% |
234,798
-41,300
| -15% | -$2.18M |
|
46
Idexx Laboratories
IDXX
$51.2B
| $12.2M | 0.47% |
37,014
-3,300
| -8% | -$1.09M |
|
47
Acadia Pharmaceuticals
ACAD
$4.3B
| $12.2M | 0.46% |
250,743
+29,144
| +13% | +$1.41M |
|
48
IQVIA
IQV
$31.3B
| $11.7M | 0.44% |
82,266
| – | – |
|
49
Ionis Pharmaceuticals
IONS
$9.46B
| $11.4M | 0.43% |
193,201
| – | – |
|
50
Zimmer Biomet
ZBH
$20.8B
| $11.3M | 0.43% |
97,493
+16,980
| +21% | +$1.97M |
|